Detalles de la búsqueda
1.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet;
397(10271): 281-292, 2021 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485453
2.
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Br J Cancer;
124(5): 951-962, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33339894
3.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Br J Cancer;
125(12): 1666-1676, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34663950
4.
Evaluation of UV-C Decontamination of Clinical Tissue Sections for Spatially Resolved Analysis by Mass Spectrometry Imaging (MSI).
Anal Chem;
93(5): 2767-2775, 2021 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33474935
5.
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Br J Cancer;
119(10): 1233-1243, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30385821
6.
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
J Clin Invest;
134(2)2024 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37934611
7.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Nat Commun;
15(1): 1700, 2024 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402224
8.
Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach.
Mol Ther;
20(10): 1953-67, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22760542
9.
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.
J Histochem Cytochem;
71(5): 237-257, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37119278
10.
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Cancers (Basel);
15(16)2023 Aug 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37627223
11.
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Cancer Res;
82(6): 1140-1152, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35078817
12.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Clin Cancer Res;
28(20): 4536-4550, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35921524
13.
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Cancer Med;
10(9): 3045-3058, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811746
14.
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Clin Cancer Res;
27(19): 5213-5224, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301752
15.
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Oncogene;
39(25): 4869-4883, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32444694
16.
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Mol Cancer Ther;
19(1): 13-25, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31534013
17.
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.
Oncotarget;
8(67): 110904-110913, 2017 Dec 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29340025
18.
Counteracting bone fragility with human amniotic mesenchymal stem cells.
Sci Rep;
6: 39656, 2016 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27995994
19.
Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta.
Stem Cells Dev;
23(3): 262-76, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24028330
20.
Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics.
Stem Cells Dev;
22(3): 444-58, 2013 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23050522